Cumulative incidence of hepatocellular carcinoma and hepatitis B surface antigen Seroclearance after Nucleos(t) ide analogue-induced hepatitis B e antigen Seroclearance

BACKGROUND: Hepatitis B e antigen (HBeAg) seroclearance has been considered as the treatment endpoint in HBeAg-positive patients with chronic hepatitis B (CHB). Although HBeAg seroclearance has been accomplished, some aspects are yet unclear. We investigated the cumulative incidence of hepatocellula...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Hyun Woong, Lee, Jung Il, Kim, Saein, Kim, Sora, Chang, Hye Young, Lee, Kwan Sik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7166314/
https://www.ncbi.nlm.nih.gov/pubmed/32305059
http://dx.doi.org/10.1186/s12876-020-01236-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7166314/
https://www.ncbi.nlm.nih.gov/pubmed/32305059
http://dx.doi.org/10.1186/s12876-020-01236-9

Ejemplares similares